ModifiedUnitedHealthcarePolicy CS079NM.C

Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for New Mexico Only)

Policy governing coverage and medical necessity of minimally invasive endoscopic and laparoscopic procedures for upper GI diseases (e.g., GERD, achalasia, gastroparesis) for UnitedHealthcare members in New Mexico.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for New Mexico Only)

Policy CodePolicy CS079NM.C

Change TypeMaterial additions and code updates

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization with documentation of refractory symptoms, prior therapies, and objective testing when requesting coverage for GES, POEM, MSA, or other device/surgical interventions.

SourceLink

POLICY UPDATE CHANGES

Gastric electrical stimulation (GES) therapy is proven and medically necessary for treating refractory gastroparesis or chronic intractable nausea and vomiting secondary to diabetic or idiopathic gastroparesis.

Surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for treating refractory gastroparesis or chronic intractable nausea and vomiting secondary to diabetic or idiopathic gastroparesis.

Language indicating functional lumen imaging probe technology is unproven and not medically necessary for diagnosing achalasia was removed.

Medical records documentation requirements added stating benefit coverage is determined by federal, state, or contractual requirements and that medical records may be required to assess clinical criteria and must support medical necessity.

Added CPT codes 43647, 43648, 43659, 43881, 43882, 64590, and 64595 to applicable codes.

Updated definition of 'Gastroparesis' and updated Description of Services, Clinical Evidence, FDA, and References to reflect current information.

GES; pyloroplastyProcedures newly noted as medically necessary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

~20Document sections provided

83% vs 81.7%POEM 2‑yr clinical success

70%G-POEM ~1‑yr success

Coverage and Medical Necessity Criteria

GES - Medically necessary

Covered when ALL of the following are met:

GES for refractory gastroparesis: Gastric electrical stimulation (GES) therapy is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.failed other therapies / refractory

Refer to the FDA section for labeling and Humanitarian Device Exemption (HDE) information.

Pyloroplasty - Medically necessary

Surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.failed other therapies / refractory

Evidence supports symptom and gastric emptying improvement; pyloric interventions frequently recommended in systematic reviews and by SAGES.

POEM - Medically necessary (achalasia, DES)

POEM for achalasia or DES: Per oral endoscopic myotomy (POEM) is proven and medically necessary for treating individuals with Achalasia or Diffuse Esophageal Spasm.

Consider local expertise and counseling regarding increased post-POEM reflux risk; POEM is an accepted alternative to laparoscopic myotomy based on society guidance and comparative trials.

POEM - Not medically necessary (other indications)

POEM for other indications: Per oral endoscopic myotomy (POEM) is unproven and not medically necessary for indications other than Achalasia or Diffuse Esophageal Spasm (for example, Zenker's diverticula) due to insufficient evidence of efficacy.

Evidence for POEM in other indications is limited and not sufficient to support routine coverage.

G-POEM - Not medically necessary

G-POEM for gastroparesis: Gastric per oral endoscopic myotomy (G-POEM) is unproven and not medically necessary for the treatment of gastroparesis.

Current evidence is limited in quality and duration; randomized and observational data are insufficient to establish long-term safety and efficacy for routine coverage.

Endoscopic/endoluminal therapies for GERD - Not medically necessary

Endoscopic/endoluminal therapies for GERD: Endoscopic therapies (including radiofrequency Stretta, endoscopic plication/suturing systems such as EndoCinch, NDO Plicator, GERDx, MUSE, EsophyX/TIF, injection or implantation (e.g., Plexiglas, Durasphere), and LINX) are considered unproven and not medically necessary for treating GERD due to insufficient high-quality evidence of durable efficacy and safety.

Specific devices such as GERDx have not received FDA approval; randomized trials and systematic reviews show inconsistent physiologic improvement and limited long-term durability.

Coverage considerations for device and endoscopic/surgical interventions

Coverage decisions reference specialty guidance and comparative effectiveness evidence; interventions are generally considered for medically refractory cases after failure of standard therapies.

General coverage approach: Coverage decisions for device-based and endoscopic/surgical interventions should reference specialty society guidance and comparative evidence; interventions are typically considered for medically refractory cases after failure of standard medical therapy.failed standard therapies documented

Document prior therapies and objective testing per society guidance (ACG, AGA, SAGES).

GES candidacy: Patient has medically refractory diabetic or idiopathic gastroparesis with intractable nausea/vomiting despite standard therapies and is an appropriate candidate for GES as described by ACG/AGA guidance.failed standard therapies

ACG: HUD consideration; AGA: consider GES in refractory cases not on opioids.

Coverage summary by procedure

Summary of coverage stance based on available evidence in these sections:

Z-POEM for Zenker's diverticulum: Observational comparative data suggest Z-POEM may be a feasible alternative to flexible endoscopic septotomy with potentially higher clinical success, but studies are retrospective, single-center, and definitions vary; consider only in expert centers with documentation of rationale and informed consent.

Further prospective long-term comparative data required.

G-POEM for refractory gastroparesis: Evidence from observational studies and limited RCTs shows symptomatic improvement in many patients (approximately 70% one-year success in some series), but overall evidence quality is low and long-term durability is uncertain; careful case selection and prior authorization recommended.

Serious adverse events have been reported in RCTs; larger trials needed.

Stretta (radiofrequency for GERD): Evidence is low to very low quality with mixed results; randomized sham-controlled trials have not consistently demonstrated benefit over sham, therefore Stretta remains unproven for routine coverage and should be considered only after careful patient selection and shared decision-making.

Candidate selection

Coverage consideration depends on demonstrated objective GERD, prior medical therapy, and device-specific evidence of benefit and durability.

General candidate requirements: Patient has documented GERD with objective testing (e.g., pathologic esophageal acid exposure or endoscopic evidence), persistent symptoms despite optimized PPI therapy or PPI dependence, and appropriate anatomy (e.g., small/absent hiatal hernia when specified).objective testing documented; prior PPI therapy optimized

Most studies required documentation of PPI use and objective testing prior to procedures.

Device-specific stance

Device- and evidence-based coverage stance (summary):

Stretta may improve symptoms and reduce PPI use in some patients but evidence quality is low and comparative effectiveness versus surgery is uncertain; use only with shared decision-making when alternatives are not appropriate.

ECRI and Hayes reviews call for larger RCTs.

Endoscopic plication/suturing (EFTP, EndoCinch): Endoscopic plication/suturing shows symptom improvement and reduced PPI reliance in some trials but long-term durability is uncertain; consider investigational or limited coverage per payer criteria.

Randomized trials demonstrate short-to-mid-term benefit but many studies are small with loss to follow-up.

GERDx / MUSE / EsophyX (TIF): EsophyX/TIF and related endoscopic fundoplication devices provide symptomatic improvement and reduced PPI use in many patients, but evidence varies and long-term physiologic improvement is limited; coverage should consider device-specific evidence and patient selection.

Systematic reviews report short-term symptom benefit with limited long-term pH normalization.

Procedure-specific conditional coverage

Coverage stance is conditional based on available evidence and documented refractory GERD:

TIF (EsophyX) coverage considerations: TIF may provide short- to mid-term symptom improvement and PPI reduction in selected patients with small or absent hiatal hernia and objective reflux; however evidence shows decreased efficacy over time and limited long-term pH normalization—coverage may be granted when documented failure of medical therapy, appropriate diagnostic workup, and informed consent regarding limited long-term durability are present.documented failure of medical therapy; appropriate diagnostic workup

Supported by systematic reviews and RCTs showing symptom improvement but limited physiologic improvement and durability.

LINX (MSA) coverage considerations: LINX (magnetic sphincter augmentation) shows high rates of patient satisfaction and PPI discontinuation in many studies, but long-term safety (erosion, explantation) and comparative effectiveness versus fundoplication remain uncertain—coverage may be considered for patients with pathologic reflux and documented failure or intolerance of medical therapy after standard diagnostics and counseling about device-specific risks.documented pathologic reflux; failed or intolerant to medical therapy

Supported by RCT evidence of regurgitation relief and multiple meta-analyses indicating promising outcomes but need for longer follow-up.

Magnetic sphincter augmentation (MSA) — when to consider

Coverage considerations reflected by guideline recommendations and trial evidence

MSA consideration: Patient has moderate-to-severe regurgitation or objective evidence of GERD despite optimized PPI therapy; diagnostic workup (upper endoscopy, ambulatory pH monitoring, esophageal manometry) completed; discuss options including MSA versus fundoplication with shared decision-making.diagnostic workup completed; persistent regurgitation despite PPI

Bell et al. RCT demonstrated superior regurgitation relief with MSA versus double-dose PPI; ACG recommends consideration of MSA as an alternative to fundoplication.

Endoscopic antireflux therapies — guideline context

Guideline-based procedural selection considerations

Alternative procedures: Transoral incisionless fundoplication (TIF) may be considered for patients with troublesome regurgitation or heartburn who do not want antireflux surgery and lack severe esophagitis or large hiatal hernia; Stretta is not routinely recommended by some societies because of inconsistent efficacy data.

Recommendations based on ACG, ASGE, and SAGES guidance acknowledging variable evidence and importance of patient selection.

Refractory gastroparesis interventions

Covered when ALL of the following are met (policy-level statements in excerpt):

GES for refractory gastroparesis: Gastric electrical stimulation (GES) is considered proven and medically necessary for treatment of refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to diabetic or idiopathic gastroparesis.refractory / failed other therapies

Refer to FDA section for labeling/HDE information and applicable society guidance.

Surgical pyloroplasty for refractory gastroparesis: Surgical pyloroplasty (open or laparoscopic) is considered proven and medically necessary for treatment of refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to diabetic or idiopathic gastroparesis.refractory / failed other therapies

Systematic reviews and SAGES support pyloroplasty as an effective surgical option.

Endoluminal therapy with GERDx™ is considered investigational and not medically necessary for treatment of GERD because the device has not received U.S. Food and Drug Administration (FDA) approval and available evidence is insufficient to establish safety and effectiveness.

Gastric electrical stimulation (GES) is discussed as a Humanitarian Use Device (HUD) option for medically refractory diabetic or idiopathic gastroparesis; guideline statements (ACG, AGA) support consideration of GES for patients with refractory, intractable nausea and vomiting who have failed standard therapies. Coverage and use should follow HUD labeling and FDA/HDE information and documentation of refractory symptoms and prior therapy attempts is expected.

Several procedures are identified as lacking sufficient high‑quality evidence or long‑term safety/durability data (for example, some novel endoscopic therapies for GERD and certain indications for G‑POEM). These procedures remain unproven and not medically necessary until larger, well‑designed studies with longer follow‑up demonstrate consistent patient‑oriented benefit and acceptable safety.

Procedures performed without prior objective confirmation of GERD (for example, documented pathologic esophageal acid exposure or endoscopic evidence) or without adequate documentation of an optimized trial of medical therapy (commonly at least 6 months of daily PPI use in study populations) are not supported by the evidence and may be excluded from coverage.

Polymer injection and implantation techniques (eg, Plexiglas®, Durasphere®) intended to provide bulking of the gastroesophageal junction have insufficient evidence to establish long‑term safety and effectiveness and therefore are considered not medically necessary.

Per the FDA labeling for the Enterra™ Therapy System (GES approved under an HDE), known contraindications include gastric obstruction or pseudo‑obstruction, prior gastric resection, prior fundoplication, eating disorders, history of seizures, primary swallowing disorders, chemical dependency, and psychogenic vomiting; use outside labeled indications may lead to denial.

Previous language excluding functional lumen imaging probe technology for diagnosing achalasia was removed in this revision. Benefit coverage remains subject to applicable federal, state, or contractual requirements and medical‑record documentation may be requested to determine whether clinical criteria are met.

G‑POEM for gastroparesis is currently considered unproven and not medically necessary because available studies are heterogeneous, generally low quality, and long‑term durability and comparative effectiveness versus alternatives (eg, pyloroplasty, GES) remain uncertain. Similarly, POEM performed for indications other than achalasia or diffuse esophageal spasm is unproven and not medically necessary.

Z‑POEM (Zenker’s POEM) evidence is limited by small, retrospective studies and short follow‑up; long‑term comparative effectiveness and durability are uncertain, so routine use outside of research or specialized centers is not supported.

Endoscopic therapies for GERD (including Stretta, endoscopic plication/suturing systems such as EndoCinch, GERDx, MUSE, and TIF/EsophyX) are considered unproven and not medically necessary for routine treatment of GERD due to limited, low‑quality evidence, inconsistent physiologic improvements, and uncertain long‑term durability.

Some endoscopic therapies demonstrate symptomatic improvement in the short term but show progressive loss of effect on symptoms and objective measures over longer follow‑up (eg, up to 60 months in reported series); this loss of durability is a reason these therapies are not routinely considered established alternatives to standard surgical or medical approaches.

Transoral incisionless fundoplication (TIF) may provide short‑ to mid‑term symptom improvement and reduced PPI use in selected patients, but evidence indicates decreased efficacy over time and limited physiologic normalization of acid exposure; therefore TIF should not be considered a reliable long‑term alternative to PPI therapy or laparoscopic Nissen fundoplication when objective physiologic abnormalities are present.

Procedures with inconsistent, low‑quality, or conflicting evidence for long‑term efficacy (for example, Stretta per some guideline evaluations) are not routinely recommended as primary antireflux therapy; use should be restricted to carefully selected patients with documented refractory disease and after discussion of uncertain long‑term benefits.

Note: language that previously excluded a specific diagnostic technology (functional lumen imaging probe) was removed in this revision. Regardless, coverage determinations continue to depend on federal, state, or contractual requirements and must be supported by the member’s medical record, which may be requested.

Applicable Codes and Coding Notes

Applicable CPT Codes (part 1)CPT

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed.
43289	Unlisted laparoscopy procedure, esophagus.
43497	Lower esophageal myotomy, transoral (i.e., peroral endoscopic myotomy [POEM]).
43499	Unlisted procedure, esophagus.
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum

Applicable CPT Codes (part 2)CPT

43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659	Unlisted laparoscopy procedure, stomach.
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open.
43882	Revision or removal of gastric neurostimulator electrodes, antrum, open.
43999	Unlisted procedure, stomach.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array

Document does not list CPT/ICD codes in this excerptmixed

No codes listed

Procedure codes mentioned implicitlymixed

No codes listed

Coding references / diagnostics mentionedmixed

Not explicitly listed in text

No CPT/HCPCS codes were provided in the extracted text; document lists diagnostic tests (endoscopy, pH monitoring, manometry) but not procedure codes for TIF or LINX.

FDA submission/clearance identifiersmixed

P100049	PMA number referenced for LINX Reflux Management System (FDA PMA P100049)
K233240	FDA 510(k) Number referenced for GERDx-System

Applicable CPT codes added in this revisionCPT

43647	CPT code added (exact description not in excerpt)
43648	CPT code added (exact description not in excerpt)
43659	CPT code added (exact description not in excerpt)
43881	CPT code added (exact description not in excerpt)
43882	CPT code added (exact description not in excerpt)
64590	CPT code added (exact description not in excerpt)
64595	CPT code added (exact description not in excerpt)

Gastric emptying test — objective evidence note

Test requiredObjective evidence of delayed gastric emptying required for diagnosis of gastroparesis; gastric scintigraphy is the reference standard for measurement of gastric emptying.

Accepted modalitiesGastric emptying scintigraphy is specified as the reference standard; other modalities not specified in this excerpt.

PurposeDemonstrates delayed gastric emptying in symptomatic patients to support consideration of interventions like GES or pyloroplasty.

Clinical success threshold (Eckardt score)

Clinical success definition

Prior Authorization, Documentation, and Operational Guidance

Note

Applicable procedure codes (reference)

Codes listed in the policy are provided for reference and may require prior authorization; listing does not guarantee coverage or payment. Relevant CPT codes include 43210, 43257, 43284, 43289, 43497, 43499, 43647, 43648, 43659, 43881, 43882, 43999, 64590, and 64595.

43210, 43257, 43284, 43289, 43497, 43499
43647, 43648, 43659, 43881, 43882, 43999
64590, 64595

Prior Authorization

Prior authorization: demonstrate refractory disease

Prior authorization submissions should document that the patient has refractory disease and has failed standard medical or endoscopic therapies; include prior treatments and specialty recommendations to support medical necessity.

Document prior medical and endoscopic therapies and that symptoms are refractory
Include rationale and any specialty society recommendations cited

Clinical Background and Rationale

Gastroparesis is characterized by delayed gastric emptying leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis requires objective evidence of delayed gastric emptying (scintigraphic gastric emptying testing is the reference standard) and assessment of symptom severity and response to medical therapy when considering interventions.

Key Definitions

Achalasia

DefinitionAchalasia: primary esophageal motor disorder characterized by degeneration of the myenteric plexus, impaired EGJ relaxation, and loss of organized peristalsis.

Typical manifestationsPresents with dysphagia and impaired esophageal emptying; diagnosed with esophageal manometry and supportive studies.

Relevance to proceduresPOEM is an indicated treatment for achalasia per the policy when diagnostic criteria and candidate selection are met.

Diffuse Esophageal Spasm

DefinitionDiffuse esophageal spasm: rare motility disorder with simultaneous, uncoordinated or rapidly propagated contractions accompanied by dysphagia.

Clinical featuresCan present with chest pain and dysphagia; diagnosis based on manometry showing simultaneous contractions.

Policy Updates

2026-04-01Material changeLatest

Added GES and surgical pyloroplasty as proven and medically necessary for refractory gastroparesis or chronic intractable nausea/vomiting secondary to diabetic or idiopathic gastroparesis; language relocated from another UnitedHealthcare policy.

2026-04-01Material change

Removed prior language indicating functional lumen imaging probe technology is unproven and not medically necessary for diagnosing achalasia.

2026-04-01Material change

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for New Mexico Only)

Policy CodePolicy CS079NM.C

Change TypeMaterial additions and code updates

Effective DateApr 1, 2026

Next Review DateN/A

SourceLink

On This Page

Pyloric intervention role:

Pyloroplasty or other pyloric interventions may be recommended as a surgical option for refractory gastroparesis and have shown symptom and gastric emptying improvements in systematic reviews.

Systematic reviews (Zoll 2018) and SAGES support laparoscopic pyloroplasty as an effective option.

POEM candidacy and counseling: For achalasia or spastic esophageal disorders, candidate selection should include diagnostic testing (esophageal manometry, timed barium esophagram) and counseling about increased reflux risk after POEM.objective diagnostic testing documented

Randomized and systematic evidence supports POEM efficacy but notes higher post-procedure reflux incidence.

Hayes and ECRI reviews cite substantial uncertainty regarding comparative effectiveness.

Eckardt score ≤ 3 is used to define clinical success in achalasia studies.

Use in trialsEckardt score applied at follow-up time points (eg, 1–24 months) to compare POEM and surgical myotomy outcomes.

Composite assessmentEckardt score used alongside objective measures (LES pressure, timed barium esophagogram) in RCTs to define success.

Minimum duration of PPI therapy

Minimum PPI durationMost TIF and related studies enrolled patients with >6 months of daily PPI use or chronic PPI dependence prior to intervention.

Documentation expectationStudies and policy recommend documenting duration and response to PPI therapy (eg, >6 months) before considering endoscopic antireflux procedures.

Comparator roleOptimized PPI therapy is the common comparator in trials evaluating endoscopic antireflux procedures; inadequate response to PPI is a prerequisite for many interventions.

Prior Authorization

G-POEM prior authorization recommended

Because evidence for G-POEM is limited, prior authorization is reasonable and reviewers should request objective symptom scores (e.g., GCSI), gastric emptying study results, prior medical and procedural therapies, and the clinical rationale for G-POEM.

Provide GCSI scores and gastric emptying study (GES) results
Document prior medical therapy and prior pyloric-directed or less-invasive interventions

Prior Authorization

Prior authorization likely required for endoscopic fundoplication/TIF

Prior authorization is appropriate for endoscopic fundoplication and transoral incisionless fundoplication (TIF); expect review of objective testing, prior optimized PPI therapy, and symptom burden as part of the authorization.

Include objective reflux testing or documented abnormal pH when available
Document duration and response to optimized PPI therapy (often >6 months)

Prior Authorization

Prior authorization for LINX/MSA and surgical antireflux procedures

Submit prior authorization when requesting LINX/MSA or other surgical antireflux procedures; documentation should include preoperative diagnostic testing and evidence of refractory symptoms despite PPI therapy.

Provide GERD-HRQL, upper endoscopy, ambulatory pH monitoring, and manometry results
Document failure or intolerance of optimized medical therapy

Documentation Required

Device approval and labeling verification

Confirm device approvals, labeled indications, and contraindications as part of the authorization review; device-specific labeling (e.g., HDE for Enterra, PMA/510(k) status for antireflux devices) should be verified.

Confirm Enterra HDE indication and FDA labeling/contraindications
Verify FDA clearance/approval status for EsophyX, Stretta, EndoCinch, and other devices

Billing Rule

Prior authorization and applicable CPT codes — documentation may be required

Prior authorization and medical-record documentation may be required to determine that members meet policy clinical criteria and applicable federal/state/contractual coverage rules; inclusion of applicable CPT codes with the request may be necessary.

Include applicable CPT codes (see policy code list) in the authorization request
Provide complete medical-record documentation to support medical necessity

Step Therapy

Step therapy

The policy excerpt does not specify a formal step therapy algorithm within this document.

Step Therapy

Step therapy considerations for gastroparesis

Guidance and evidence indicate pyloric-directed interventions (e.g., pyloroplasty) are often considered before or as alternatives to GES for refractory gastroparesis; prior pyloric-directed therapy and its outcomes may be relevant to authorization.

Document prior pyloric interventions and clinical response when available
Explain why GES is preferred over pyloric-directed options if applicable

Step Therapy

Step therapy expectation — consider prior medical management before G-POEM

Consideration of prior medical management and less-invasive therapies before G-POEM is supported by the literature; authorization should reflect documented failure of prior therapies.

Document attempts at optimized medical therapy and other less-invasive treatments
Provide timeline showing refractory symptoms despite prior management

Step Therapy

Conservative therapy prerequisite

Conservative management including optimized PPI therapy is the common comparator in GERD studies; documentation of inadequate response to optimized PPI therapy is commonly required before considering endoscopic or surgical antireflux interventions.

Show record of optimized PPI therapy and symptom response
Include duration and dosing of PPI therapy

Step Therapy

Requirement for prior medical therapy (e.g., ≥6 months PPI)

Most studies and trials enrolled patients with chronic GERD refractory to PPI therapy; authorization requests commonly should document at least six months of daily PPI use or chronic PPI dependence prior to procedures.

Document duration of daily PPI use (commonly >6 months) and continued symptoms
Describe attempts at dose optimization or alternative medical management

Step Therapy

Consideration after PPI failure for MSA

For consideration of MSA (LINX), evidence and guidelines indicate the procedure is appropriate for patients with persistent regurgitation despite optimized PPI therapy; prior medical therapy failure should be documented in the authorization.

Provide objective reflux testing and documentation of persistent regurgitation while on optimized PPI
Include discussion of alternative surgical options and shared decision-making

Step Therapy

Refractory therapy expectation — GES and pyloroplasty for refractory cases

GES and surgical pyloroplasty are indicated for refractory gastroparesis after failure of other therapies; authorization should confirm prior conservative/medical therapy attempts and refractory status.

Document prior medical treatments for gastroparesis and continued intractable symptoms
Include objective evidence such as gastric emptying study results when available

Documentation Required

Medical records required for review

The patient's medical record must contain relevant medical history, physical exam findings, and results of pertinent diagnostic tests or procedures to support medical necessity and must be made available upon request for review.

Ensure records are legible, maintained in the medical record, and retrievable upon request
Include history, exam, and test results that directly support the requested service

Documentation Required

Required clinical documentation (symptom scores, objective testing)

Required clinical documentation for review includes validated symptom scores (e.g., PAGI-SYM, GCSI, Eckardt for achalasia), objective testing (gastric emptying scintigraphy, esophageal pH monitoring, manometry, timed barium esophagogram), and documentation of refractory status to standard therapies.

Provide specific validated symptom score results and dates
Attach results of objective testing (GES, pH monitoring, manometry) relevant to the indication

Documentation Required

Suggested clinical documentation for novel procedures

For novel procedures such as G-POEM, include documentation demonstrating refractory symptoms despite medical therapy, objective severity measures (e.g., GCSI scores, gastric emptying study results), prior treatments attempted, and rationale for selecting the novel procedure.

Include trial of medical therapy details and objective severity measures
Provide justification for G-POEM and documentation of informed consent discussing limited evidence

Documentation Required

Documentation should include details of prior PPI therapy and objective testing

Documentation should include duration and response to prior PPI therapy, objective testing supporting GERD diagnosis (pH monitoring, endoscopy findings, hiatal hernia size, Hill grade), and validated symptom/quality-of-life scores (GERD-HRQL, RSI) pre- and post-procedure when applicable.

Record exact PPI regimen, duration, and response
Attach endoscopy, pH monitoring, and manometry reports as applicable

Documentation Required

Preoperative diagnostic testing for LINX

Preoperative diagnostic assessment for LINX commonly includes GERD-HRQL questionnaire, upper GI endoscopy, barium swallow, ambulatory esophageal pH monitoring, and esophageal manometry; include these studies in the authorization when applicable.

Attach GERD-HRQL and objective testing reports
Document hiatal hernia size and esophagitis grading if present

Documentation Required

Symptom and medication documentation

Include symptom-score results and detailed medication history (including PPI dosing and duration) in records submitted for prior authorization and medical necessity review.

Submit validated questionnaire scores (GERD-HRQL, GERSS, RSI) with dates
Document pre-procedure and prior PPI use and any changes after therapy attempts

Documentation Required

Pre-procedure diagnostic workup

Pre-procedure diagnostic workup commonly includes validated symptom scores (GERD-HRQL), upper endoscopy, barium swallow, ambulatory esophageal pH monitoring, and esophageal manometry; include these evaluations to support appropriate patient selection for antireflux procedures.

Provide reports of pH monitoring and manometry when available
Include endoscopy findings and hiatal hernia measurement

Documentation Required

Medical records requirements (policy excerpt)

The patient's medical record must fully support medical necessity, including relevant medical history, physical exam, and results of pertinent diagnostic tests or procedures; records must be legible, maintained in the medical record, and made available upon request.

Ensure documentation is complete and available for review upon request
Link objective test results to the clinical indication for the requested intervention

Denial Risk

Documentation adequacy — insufficient documentation may lead to denial

Insufficient or incomplete documentation that does not fully demonstrate that the member meets the policy's clinical criteria may result in a denial; medical records must be provided on request to support medical necessity determinations.

Provide complete prior-treatment history, objective testing, and validated symptom scores
Anticipate requests for additional records to substantiate medical necessity

Denial Risk

GES humanitarian-use considerations

GES may be considered as a humanitarian use device (HUD) for medically refractory diabetic or idiopathic gastroparesis; lack of evidence of refractory status or use outside HUD-defined indications can lead to noncoverage or denial.

Document that patient meets HUD-labeled indications (chronic intractable nausea/vomiting secondary to diabetic or idiopathic gastroparesis, age 18–70)
Include supporting guideline statements (ACG/AGA) and symptom/test documentation

Denial Risk

POEM documentation of prior therapy

For POEM, lack of documentation of prior standard therapies or an inappropriate indication (POEM indicated only for achalasia or diffuse esophageal spasm) may trigger review or denial; also counsel patients about higher post-procedure reflux risk.

Confirm indication is achalasia or diffuse esophageal spasm and include manometry/timed barium swallow results
Document prior therapy attempts and informed counseling regarding reflux risk post-POEM

Denial Risk

Evidence insufficiency may trigger denial

Insufficient high-quality evidence or lack of long-term durability data for G-POEM and other novel endoscopic procedures may lead to coverage denial or requests for additional documentation.

Provide long-term outcome data when available or rationale for use within research/specialized centers
Anticipate requests for objective measures correlating symptom improvement with physiologic testing

Denial Risk

Insufficient evidence / inadequate pre-procedure evaluation may lead to denials

Procedures supported primarily by small, nonrandomized, or short-duration studies without adequate pre-procedure evaluation (e.g., absence of optimized PPI therapy or objective reflux testing) may be denied for lack of demonstrated long-term efficacy or appropriate patient selection.

Document optimized medical therapy and objective testing before pursuing novel or investigational procedures
Provide larger or controlled-study evidence when available to support efficacy

Denial Risk

Long-term decreased efficacy and PPI resumption risk after TIF; potential LINX safety/efficacy concerns

Long-term decreased efficacy and resumption of PPI therapy have been reported after TIF; limited long-term safety/effectiveness data for LINX may also trigger review or denial if long-term benefit is not documented.

Include long-term follow-up data showing sustained symptom relief or PPI discontinuation when available
Document any subsequent PPI use or device removals/explants

Denial Risk

Off-label / contraindicated use risk

Use of devices outside their labeled indications or in the presence of FDA-listed contraindications (for example, Enterra used outside the HDE indications) may lead to coverage denial; verify intended use aligns with device labeling.

Confirm intended use matches FDA-labeled indications and contraindications
Provide justification and documentation if use outside labeling is requested

Documentation Required

Documentation-dependent coverage (federal/state/contractual requirements)

Coverage determinations depend on federal, state, or contractual requirements and are documentation-dependent; if requested, medical records must be provided to demonstrate that the member meets clinical criteria for coverage.

Be prepared to supply full medical records and objective test results upon request
Note that contractual or state/federal mandates may supersede policy language

Therapeutic contextPOEM may be considered for diffuse esophageal spasm per policy when indicated.

GERD

DefinitionGastroesophageal reflux disease (GERD): condition where the lower esophageal sphincter relaxes too often or weakens, allowing reflux of stomach contents into the esophagus.

ComplicationsPersistent GERD can lead to esophagitis, strictures, Barrett's metaplasia, and esophageal adenocarcinoma.

Diagnostic approachObjective testing (eg, pH monitoring, endoscopy) and documentation of failed/optimized PPI therapy are expected for procedural consideration.

Gastroparesis

DefinitionGastroparesis: delayed gastric emptying due to abnormal or absent gastric motility, presenting with nausea, vomiting, early satiety, bloating, and postprandial fullness.

Diagnostic requirementDiagnosis requires objective evidence of clearly delayed gastric emptying in symptomatic patients; scintigraphy is the reference standard.

EtiologyMay be idiopathic, diabetic, medication-induced, or post-surgical; diabetes is a common cause.

Humanitarian Use Device (HUD)

DefinitionHumanitarian Use Device (HUD): an FDA designation allowing devices to treat conditions affecting a small number of patients where evidence is limited; Enterra (GES) has an HDE for refractory diabetic or idiopathic gastroparesis.

Guideline contextACG notes GES may be considered as an HUD for medically refractory diabetic or idiopathic gastroparesis (conditional recommendation; low-quality evidence).

ImplicationHUD status implies limited evidence and the need to follow labeling and specialty guidance when considering coverage.

Clinical success (achalasia studies)

Clinical success metricAchalasia studies commonly define clinical success as an Eckardt score ≤ 3 at follow-up.

Use in comparative trialsEckardt score used as primary outcome in trials comparing POEM and LHM/fundoplication (eg, Werner 2019).

Complementary measuresOften combined with objective measures (LES pressure, timed barium esophagogram) to confirm treatment effect.

Z-POEM

DefinitionZ-POEM: Zenker's peroral endoscopic myotomy, an endoscopic septotomy/myotomy technique for treatment of symptomatic Zenker's diverticulum.

Evidence summaryObservational comparative data suggest Z-POEM may be a feasible alternative to flexible endoscopic septotomy in expert hands but long-term comparative data are limited.

RecommendationConsider Z-POEM in specialized centers with appropriate expertise and documentation; further prospective long-term data needed.

G-POEM

DefinitionG-POEM: gastric peroral endoscopic myotomy — an endoscopic pyloric myotomy technique proposed for refractory gastroparesis.

Evidence statementCurrent evidence is insufficient in quality to support safety, efficacy, and long-term effectiveness; study populations are heterogeneous and many reports come from tertiary centers.

Policy stanceG-POEM is considered unproven and not medically necessary for treatment of gastroparesis in this policy excerpt.

Stretta

DefinitionStretta: esophageal radiofrequency energy treatment delivering RF energy to the gastroesophageal junction intended to reduce GERD symptoms and PPI use.

Evidence summaryEvidence is low to very low quality with mixed results; RCTs have not consistently shown benefit over sham, and comparative effectiveness versus fundoplication is uncertain.

Policy implicationStretta is considered unproven for routine treatment of GERD; if considered, document refractory symptoms and prior therapies.

Stretta (alternate)

Alternate wordingRadiofrequency Stretta delivers RF energy to the LES/gastroesophageal junction to attempt symptom improvement and reduce PPI dependence; randomized sham-controlled trials (eg, Zerbib 2020) did not show consistent benefit.

Clinical trial findingsZerbib et al. (2020) randomized patients to Stretta or sham and found no significant difference in days without heartburn or PPI use at 24 and 48 weeks.

Evidence needsLarger multicenter RCTs with longer follow-up are needed to clarify effectiveness and comparative performance versus surgical options.

Endoscopic full-thickness fundoplication (EFTP)

DefinitionEndoscopic full-thickness fundoplication (EFTP): an endoscopic suturing/plication technique to create a fundoplication-like effect via transoral approaches (devices include GERDx, MUSE, EsophyX/TIF).

Trial evidenceRandomized and prospective studies report symptom improvement and reduced PPI dependence in many patients, but long-term durability and physiologic normalization remain uncertain.

Policy noteEFTP procedures show promise but evidence quality and long-term outcomes vary; consider device-specific data and patient selection when evaluating coverage.

TIF (Transoral Incisionless Fundoplication)

DefinitionTIF (Transoral Incisionless Fundoplication): a transoral procedure using the EsophyX device to reconstruct the gastroesophageal valve and reduce reflux without abdominal incisions.

Evidence summaryStudies report symptomatic improvement and reduced PPI use in selected patients (often with small or no hiatal hernia), but long-term physiologic improvement and durability are limited in some series.

Candidate profileTypically considered for patients with chronic GERD refractory to PPI, small/absent hiatal hernia, and objective reflux testing; document >6 months PPI use in many trials.

TIF (EsophyX) alternate entry

Alternate entryEsophyX (TIF) studies often enrolled patients with >6 months of daily PPI use and objective reflux (eg, abnormal esophageal acid exposure); randomized sham-controlled trials and long-term follow-up show mixed but sometimes durable symptom control.

LimitationsMany studies lack long-term physiologic normalization (pH) and have variable follow-up and loss to follow-up, limiting conclusions about durability.

Clinical implicationCoverage decisions for TIF should consider documented refractory symptoms, objective testing, hiatal hernia size, and informed consent regarding durability.

LINX / MSA

DefinitionLINX / MSA (Magnetic Sphincter Augmentation): laparoscopically implanted ring of magnetic beads around the LES to augment sphincter function and reduce reflux.

Evidence summaryShort-term studies and meta-analyses report high rates of PPI discontinuation and symptom improvement; long-term safety (erosion, explantation) and comparative effectiveness versus fundoplication require further study.

When consideredMay be considered for patients with pathologic reflux and persistent regurgitation despite optimized PPI therapy after appropriate diagnostic workup; shared decision-making recommended.

Polymer injection/bulking agents

DefinitionPolymer injection/bulking agents: injectable materials (eg, Plexiglas, Durasphere) intended to bulk the gastroesophageal junction to reduce reflux.

Evidence limitationsEvidence is limited to small case series and systematic reviews conclude insufficient evidence to determine safety and effectiveness for GERD treatment.

Policy stancePolymer injection/implantation techniques are considered unproven and not medically necessary absent higher-quality evidence.

MSA / LINX (definition entry)

DefinitionMagnetic sphincter augmentation (MSA)/LINX: a laparoscopically implanted magnetic ring device designed to augment the lower esophageal sphincter to reduce reflux; approved by FDA (PMA P100049).

Regulatory noteLINX received FDA premarket approval (PMA) and device-specific labeling and contraindications should be confirmed when considering implantation.

Clinical contextRCTs show significant regurgitation relief versus double-dose PPI; consider after diagnostic workup and counseling about device risks and potential need for explantation.

TIF / EsophyX (definition entry)

DefinitionTIF / EsophyX: an endoluminal fundoplication technique using EsophyX devices cleared by FDA (510[k] lineage) for full-thickness plication and treatment of symptomatic chronic GERD in selected patients.

FDA statusEsophyX2 was cleared via 510(k) and is indicated for transoral tissue approximation, full-thickness plication, and treatment of symptomatic chronic GERD in patients who respond to pharmacologic therapy.

Clinical noteDevice-specific evidence shows symptomatic improvement and reduced PPI use for many patients; long-term physiologic normalization is variable across studies.

Enterra Therapy System

DefinitionEnterra Therapy System: a gastric electrical stimulation device approved under an HDE for chronic, intractable (drug-refractory) nausea and vomiting secondary to diabetic or idiopathic gastroparesis in adults aged 18–70.

Label contraindicationsFDA labeling indicates Enterra should not be used in patients with gastric obstruction or pseudo-obstruction, prior gastric resection, fundoplication, eating disorders, history of seizures, primary swallowing disorders, chemical dependency, or psychogenic vomiting.

Regulatory contextHDE approval reflects limited patient population and humanitarian device considerations; follow FDA labeling when evaluating candidacy.

Gastroparesis (updated definition)

Updated definitionGastroparesis: updated definition in this policy version acknowledges delayed gastric emptying with symptomatic manifestations; full updated text is provided in the policy body (scintigraphy remains reference standard).

Diagnostic requirementDiagnosis requires objective evidence of delayed gastric emptying in symptomatic patients; scintigraphy is the reference standard for measurement.

Clinical implicationsPolicy additions state GES and surgical pyloroplasty are considered medically necessary for refractory gastroparesis that has failed other therapies.

Added statement clarifying medical records documentation may be required to assess whether a member meets clinical criteria and must fully support medical necessity; documentation must be legible and made available upon request.

2026-04-01Material change

Updated definition of 'Gastroparesis' in the Definitions section.

2026-04-01Coding update

Added CPT codes 43647, 43648, 43659, 43881, 43882, 64590, and 64595 to the list of applicable procedure codes.

2026-04-01Coding updateLatest

Added CPT codes 43647, 43648, 43659, 43881, 43882, 64590, and 64595 to applicable codes in the policy.

2026-04-01Documentation requirement updateLatest

Added Medical Records Documentation language clarifying that benefit coverage is determined by federal, state, or contractual requirements and that medical records may be required to assess clinical criteria and must fully support medical necessity; records must be legible, maintained in the patient's medical record, and made available upon request.

2026-04-01Definition updateLatest

Updated the definition of 'Gastroparesis' and made additional editorial updates across Description of Services, Clinical Evidence, FDA, and References sections to reflect current information.

2026-04-01Editorial revision

Title change: previously titled 'Minimally Invasive Procedures for Gastric and Esophageal Diseases (for New Mexico Only)' and other editorial clarifications were made in the Summary of Changes.

Coverage determinations are subject to applicable federal, state, or contractual requirements. Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage; documentation must fully support medical necessity, include relevant history, physical exam, and results of pertinent diagnostic tests or procedures, be legible and maintained in the medical record, and be made available upon request.